The poor performance of industrial biotech companies after their IPOs has halted and postponed several public debuts of promising companies in years past. The industry has become known for promising too much too soon, only to surprise investors with negative developments. But Fool.com contributor Maxx Chatsko explains why that could be about to change during the remainder of 2013.
He believes several companies have set the bar precipitously low to start the year despite targeted developments expected to occur before the start of 2014. Watch the following video for his thoughts on potential positive surprises awaiting investors in Amyris (AMRS +0.00%), BioAmber (NYSE: BIOA), Codexis (CDXS +2.02%), and Solazyme (SZYM +0.00%).
